LINC01814

Across TCGA pan-cancer cohorts, LINC01814 RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of LINC01814’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where LINC01814 RNA is repressed in tumor relative to normal tissue. In most cancer types LINC01814 is over-expressed in tumor, although a few such as THCA and LIHC show the opposite, repressed pattern.

THCA, STAD, and COAD are the cancer types where LINC01814 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LINC01814 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	IV	−0.763	<.001	11	view →
STAD	Male	II,III,IV	+0.567	<.001	9	view →
COAD	Male	All	+0.347	<.001	7	view →
LUAD	All	All	+0.230	.001	7	view →
BRCA	Female	II,III,IV	+0.257	<.001	6	view →
UCEC	All	III,IV	+0.220	<.001	6	view →
CHOL	All	All	+0.733	<.001	3	view →
LUSC	All	All	+0.179	<.001	3	view →
READ	All	All	+0.582	.004	2	view →
ESCA	All	II,III,IV	+0.420	.026	2	view →
PAAD	Female	All	+0.339	.030	2	view →
BLCA	All	All	+0.215	.020	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

LINC01814–THCA

Open the THCA breakdown →